Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis

Host: Pushpa Narayanaswami, MD, FAAN

In this expert commentary, Dr. Narayanaswami highlights key messages from the Prova Education satellite symposium held at the 2025 AANEM Meeting in San Francisco. The discussion centers on the clinical application of FcRn antagonists in gMG, reviewing the rationale for FcRn blockade, approved FcRN antagonists, and pivotal clinical trial data. Differences in therapy onset, duration, administration, and tolerability are outlined, along with considerations for treatment selection based on antibody profiles and diagnostic criteria. Practical insights address use in special populations, coordination with plasma exchange, and vaccination timing, offering clinicians a concise synthesis of the symposium’s clinical guidance.